Doribax (doripenem)
- Region
- 🇪🇺 EU
- Active substance
- doripenem
- Company
- Janssen-Cilag International NV
- Status
- Withdrawn
- Therapeutic area
- Pneumonia, Ventilator-Associated; Pneumonia, Bacterial; Urinary Tract Infections; Bacterial Infections; Cross Infection
- EU approval
- Fri 25 Jul 2008
- Application
- EMEA/H/C/000891
- ATC
- J01DH04
- Official record
- www.ema.europa.eu
Indication
Doribax is indicated for the treatment of the following infections in adults: nosocomial pneumonia (including ventilator-associated pneumonia); complicated intra-abdominal infections; complicated urinary tract infections. Consideration should be given to official guidance on the appropriate use of antibacterial agents.
Regulatory milestones
No milestones recorded in the last year.
Follow Doribax
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.